Table 2.
Cross-sectional effect per unit lower eGFR-MDRD on symptom number and severity at baseline
| Symptom number (n = 980) | Symptom severity (n = 846) | |
|---|---|---|
| Unadjusted | −0.01 (−0.08; 0.07) | −0.06 (−0.34; 0.23) |
| Adjusteda | 0.004 (−0.07; 0.08) | 0.06 (−0.22; 0.34) |
a
Adjusted for: age, sex, ethnicity, country of residence, educational level, diabetes mellitus, cerebrovascular disease, myocardial infarction, hypertension, malignancy, psychiatric disease, BMI, primary kidney disease, haemoglobin and proteinuria at each specific time point (baseline, 6 or 12 months after cohort entry).